ANURAS2025-10-012025-12-31ANURAS2025-12-31ANURAS2025-04-012025-12-31ANURAS2025-10-012025-12-31in-capmkt:OtherExpenses1MemberANURAS2025-04-012025-12-31in-capmkt:OtherExpenses1MemberANURAS2025-10-012025-12-31ItemsThatWillNotBeReclassifiedToProfitAndLoss1ANURAS2025-10-012025-12-31ItemsThatWillNotBeReclassifiedToProfitAndLoss2ANURAS2025-04-012025-12-31ItemsThatWillNotBeReclassifiedToProfitAndLoss1ANURAS2025-04-012025-12-31ItemsThatWillNotBeReclassifiedToProfitAndLoss2ANURAS2025-10-012025-12-31ItemsThatWillBeReclassifiedToProfitAndLoss1ANURAS2025-10-012025-12-31ItemsThatWillBeReclassifiedToProfitAndLoss2ANURAS2025-04-012025-12-31ItemsThatWillBeReclassifiedToProfitAndLoss1ANURAS2025-04-012025-12-31ItemsThatWillBeReclassifiedToProfitAndLoss25432752025-12-31Statement15432752025-10-012025-12-31Statement1ANURAS2025-12-31StatementDynamic1I1Statement1ANURAS2025-12-31StatementDynamic1I2Statement1iso4217:INRxbrli:pureiso4217:INRxbrli:shares543275ANURASNOTLISTEDINE930P01018ANUPAM RASAYAN INDIA LIMITEDMain BoardEquity2025-04-012026-03-312026-02-142026-02-07INRMillionsQuarterlyThird quarterSingle segmentManufacturing of Industrial Chemicals2026-02-1409:06:002026-02-1409:35:00Not applicabletrue1falseNot Applicable2025-10-012025-12-31UnauditedStandalone401367000049530000406320000024440900000-1770700001088500003359200002929600006310500003635800000427400000042740000074800000-126590000-5179000004791900000000479190000-84800004707100001138480000104.224.22004.224.221. The above Standalone financial results for the Quarter and Nine months ended December 31 2025 have been prepared by the Company in accordance with Regulation 33 of SEBI Listing Obligations and Disclosure Requirements Regulations 2015 as amended and were reviewed by the Audit Committee of the Board and thereafter were approved and taken on record by the Board of Directors in their meeting held on February 14 2026. <BR> 2. Based on the management approach as defined in Ind AS 108 Operating Segments the Chief Operating Decision Maker evaluates the companys performance and allocates resources based on an analysis of various performance indicators of the business segment in which the company operates. The Company is primarily engaged in the business of custom synthesis and manufacturing of specialty chemicals which the management and CODM recognise as the sole business segment. Hence disclosure of segment wise information is not required and accordingly not provided. <BR> 3. The Board of Directors of the Company at its meeting held on July 15 2025 has approved the allotment of 3914886 fully paid up equity shares at an issue price of INR 945.11 per share comprising face value of INR 10 per share and premium of INR 935.11 per share on preferential allotment basis upon conversion of equal number of warrants after receipt of 75 percent amount i.e. INR 2775 million. The entire amount of INR 2775 million so received have been utilised for the repayment of Loans and General Corporate purposes by December 31 2025. <BR> 4. The figures of the previous period have been regrouped rearranged and or recasted wherever considered necessary. <BR> 2025-04-012025-12-31UnauditedStandalone130498700001747800001322465000082511200000-6133300003383400001020640000833760000203157000011862100000136255000001362550000238450000-660300001724200000119013000000001190130000-11740000117839000011384800001010.5910.590010.5910.59Other Expenses631050000Other Expenses2031570000Gain/(loss) on remeasurements of the defined benefits plan-13040000Income tax (expense)/income on remeasurements of the defined benefits plan4560000-8480000Gain/(loss) on remeasurements of the defined benefits plan-18050000Income tax (expense)/income on remeasurements of the defined benefits plan6310000-1174000000Effective portion of gain/(loss) on hedging instruments in a cash flow hedge0Income tax (expense)/income on effective portion of gain/(loss) on hedging instruments in a cash flow hedge00Effective portion of gain/(loss) on hedging instruments in a cash flow hedge0Income tax (expense)/income on effective portion of gain/(loss) on hedging instruments in a cash flow hedge0000-8480000-11740000Preferential Issues2023-12-0655000000002025-12-31trueCRISIL Ratings LimitedfalseNANANAAshish GuptaCompany Secretary and Compliance OfficerSurat2026-02-14Part or full repayment of LoansNA42969000000429690000001. As the date of allotment of both the securities i.e. equity shares and warrants are different we have mentioned the date of Extraordinary General Meeting i.e. December 06 2023 as the Date of raising funds in the above table which happens to be the date of approval of members for raising the funds by way of issue of equity shares and warrants under Preferential Issue. <br></br> <br></br> 2. Total issue size of Preferential Issue is mentioned in the column Amount Raised out of which <br></br> <br></br> i. Rs. 180 Crores had been received as the allotment money against 1904540 equity shares issued at Rs. 945.11 per share allotted on December 19 2023. <br></br> <br></br> ii. Rs. 92.50 Crores had been received towards 25 percent upfront amount against 3914886 warrants allotted on January 23 2024. <br></br> <br></br> iii. Rs. 277.50 Crores had been received towards remaining 75 percent amount against the aforesaid warrants which were converted into equal number of equity shares on July 15 2025. <br></br> <br></br> 3. Please note that the proceeds of preferential issue have been fully utilised as on December 31 2025.General Corporate PurposesNA12031000000120310000001. As the date of allotment of both the securities i.e. equity shares and warrants are different we have mentioned the date of Extraordinary General Meeting i.e. December 06 2023 as the Date of raising funds in the above table which happens to be the date of approval of members for raising the funds by way of issue of equity shares and warrants under Preferential Issue. <br></br> <br></br> 2. Total issue size of Preferential Issue is mentioned in the column Amount Raised out of which <br></br> <br></br> i. Rs. 180 Crores had been received as the allotment money against 1904540 equity shares issued at Rs. 945.11 per share allotted on December 19 2023. <br></br> <br></br> ii. Rs. 92.50 Crores had been received towards 25 percent upfront amount against 3914886 warrants allotted on January 23 2024. <br></br> <br></br> iii. Rs. 277.50 Crores had been received towards remaining 75 percent amount against the aforesaid warrants which were converted into equal number of equity shares on July 15 2025. <br></br> <br></br> 3. Please note that the proceeds of preferential issue have been fully utilised as on December 31 2025.